09/09/2019 | Press release | Distributed by Public on 09/09/2019 08:54
In our most popular poll thus far, over 500 people responded with their choice of antiplatelet and antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. The recently updated atrial fibrillation guidelines1 now give a Class IIa recommendation to the use of dual therapy after percutaneous coronary intervention (PCI) as reasonable choices after PCI to reduce the risk of bleeding compared with triple therapy. It appears these recommendations are slowly translating to clinical care because about one third (35%) of respondents indicated they would use dual therapy with clopidogrel and anticoagulation without aspirin. In contrast, triple therapy with aspirin and clopidogrel and either warfarin or a NOAC was the choice of treatment for more than half of respondents (54%). Use of anticoagulation with one of the newer antiplatelet agents, ticagrelor or prasugrel, was chosen in a small minority, only about 10% of respondents, likely due to the increased risk of bleeding.
Clinical Topics:Acute Coronary Syndromes, Anticoagulation Management, Arrhythmias and Clinical EP, Invasive Cardiovascular Angiography and Intervention, Anticoagulation Management and ACS, Anticoagulation Management and Atrial Fibrillation, Atrial Fibrillation/Supraventricular Arrhythmias, Interventions and ACS
Keywords:Acute Coronary Syndrome, Platelet Aggregation Inhibitors, Warfarin, Aspirin, Atrial Fibrillation, Fibrinolytic Agents, Ticlopidine, Adenosine, Percutaneous Coronary Intervention, Hemorrhage